Dogwood Therapeutics (DWTX) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dogwood Therapeutics (DWTX) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 83.7% versus a loss of 85.6%. Over five years, MREO leads with a -86.3% price change compared with -99.2% for DWTX. Mereo BioPharma Group is the larger company by market cap ($41.5 million vs $39.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DWTX | MREO |
|---|---|---|
| Share price | $1.04 | $0.26 |
| Market cap | $39.57M | $41.52M |
| 1-day change | -2.36% | -5.45% |
| YTD return | -75.12% | -37.65% |
| 1-year return | -83.68% | -85.56% |
| 5-year return | -99.16% | -86.32% |
| P/E ratio (TTM) | 0.10 | — |
| EPS (TTM) | $10.26 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $500.00K |
| Net income (latest FY) | $-34.26M | $-41.88M |
| Operating margin | — | -8021.40% |
| Net margin | — | -8375.60% |
| 52-week high | $7.04 | $2.37 |
| 52-week low | $0.901 | $0.20 |
| Distance from 52-week high | -85.31% | -89.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +1252.66% | +653.85% |
| Average volume | 89.88K | 1.24M |
| Shares outstanding | 38.23M | 159.70M |
| Employees | 8 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
DWTX vs MREO FAQ
Which is bigger, Dogwood Therapeutics or Mereo BioPharma Group?
Mereo BioPharma Group (MREO) is larger, with a market capitalization of $41.52M compared with $39.57M for Dogwood Therapeutics (DWTX).
Which stock has performed better over the past year, DWTX or MREO?
DWTX returned -83.68% over the past 12 months, compared with -85.56% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Dogwood Therapeutics and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.